Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Edgewise Therapeutics ( (EWTX) ) has provided an announcement.
On April 2, 2025, Edgewise Therapeutics announced positive top-line results from its Phase 2 CIRRUS-HCM trial of EDG-7500 in patients with both obstructive and nonobstructive hypertrophic cardiomyopathy. The trial demonstrated that EDG-7500 significantly reduced left ventricular outflow tract gradients and improved cardiac biomarkers without affecting systolic function, indicating its potential as a significant advancement for HCM treatment. The findings suggest a promising future for EDG-7500, with plans for further optimization and a Phase 3 trial in 2026, potentially impacting patients and clinicians by providing a new therapeutic option.
More about Edgewise Therapeutics
Edgewise Therapeutics is a leading biopharmaceutical company specializing in muscle disease treatments. The company focuses on developing novel therapies, such as EDG-7500, a cardiac sarcomere modulator designed to address hypertrophic cardiomyopathy (HCM) and other diastolic dysfunction diseases.
YTD Price Performance: -25.53%
Average Trading Volume: 1,186,032
Technical Sentiment Signal: Hold
Current Market Cap: $2.09B
See more insights into EWTX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue